Solventum (SOLV) is rated Very Unattractive because it shows negative economic earnings, a low return on invested capital (ROIC) of 5%, and an expensive valuation. The commonly reported Street Earnings significantly overstate Solventum's true profitability, with the 1Q26 Street EPS estimate inflated by 58% compared to Core Earnings, which provide a more accurate measure. This discrepancy highlights the flaws in GAAP and Street Earnings metrics, which can mislead investors about a company's financial health. Investors should rely on Core Earnings for a clearer picture of Solventum's performance.
Purecore Metals Inc. has signed a non-binding letter of intent with Skyharbour Resources to acquire an option to earn up to 100% interest in the Yurchison uranium property in Saskatchewan's Athabasca Basin. The property covers over 35,000 hectares an...
Shirofune has introduced Walmart Connect, an integration that allows advertisers and agencies to manage Walmart retail media campaigns alongside other digital channels within a single platform. This automation reduces manual bid adjustments and repor...
Point completed a $508.6 million rated asset-backed securitization of its Home Equity Investment (HEI) assets, marking the largest transaction ever in the HEI asset class. The deal attracted over 30 institutional investors and priced at significantly...
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
Red Light Holland, after acquiring Filament Health, has expanded its capabilities in pharmaceutical-grade psilocybin development. Filament completed a shipment of its botanical psilocybin drug candidate, PEX010, to the European Union to support multi...
